✨ Free AI Report
Vor Biopharma Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Vor Biopharma Inc.
Company Research

Vor Biopharma Inc.: Business Overview, Financials & Competitive Analysis

Vor Biopharma Inc. scores 4/10 on the AskCyborg Cyborg Score (Challenged). Early-stage cell therapy company pivoting strategy amid substantial operating losses and clinical trial headwinds. Vor reported a net loss of $32.5 million in Q1 2025 with an accumulated deficit of $489.5 million since inception. The company is winding down operations and exploring strategic alternatives.

What is Vor Biopharma Inc.'s industry? Vor Biopharma Inc. (vorbio.com) operates in Biopharmaceutical / Cell & Gene Therapy. AskCyborg classifies Vor Biopharma Inc. under Biopharmaceutical / Cell & Gene Therapy in its company registry.

Vor Biopharma is a clinical-stage cell and genome engineering company developing the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. The company aims ...

4/ 10Challenged

Cyborg Score thesis

Early-stage cell therapy company pivoting strategy amid substantial operating losses and clinical trial...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Cell & Gene Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Vor Biopharma Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Vor Biopharma Inc.

AskCyborg analysts argue the bull and bear cases for Vor Biopharma Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Vor Biopharma Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Vor Biopharma Inc. Overview

Pro stress-test →

Vor Biopharma is a clinical-stage cell and genome engineering company developing the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. The company aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.

Strategic Profile

Pro stress-test →

Vor has license agreements with Columbia University, the National Institutes of Health, and Editas Medicine for ex-vivo Cas9 gene-edited hematopoietic stem cell therapies. The company recently announced a strategic shift, winding down operations and exploring options to maximize shareholder value.

Competitive Landscape

Pro stress-test →

Vor competes in the cell therapy oncology space against companies including Adaptimmune Therapeutics, NexImmune, Oxford Biotherapeutics, and Cara Therapeutics. The market is characterized by early-stage development programs with significant clinical and commercial execution risk.

Industry Context

Vor Biopharma Inc. operates in Biopharmaceutical / Cell & Gene Therapy.

Key facts

Founded: 2015 · Headquarters: Cambridge, Massachusetts · Market cap: $191M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Vor Biopharma Inc..

  • Lead program trem-cel combines engineered hematopoietic stem cells with VCAR33 CAR-T therapy for AML treatment.
  • R&D expenses increased to $26.7 million in Q1 2025 driven by higher clinical trial costs for trem-cel and VCAR33.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Q1 2025Accumulated deficit reached $489.5 million; R&D expenses grew to $26.7 million
  • 2025Company announced strategic shift, winding down operations and exploring strategic alternatives
  • +1 moreTrack every material event for Vor Biopharma Inc. as it happens. Explore monitoring →
Get alerted when Vor Biopharma Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T ImmunotherapyEngineered T-cell therapies for hematologic malignancies→Engineered Cell TherapyAutologous engineered cell therapies for cancer→Cancer ImmunotherapyMultispecific biologics for cancer treatment→

Compare Vor Biopharma Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Vor Biopharma Inc. operates in Biopharmaceutical / Cell & Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Cell & Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Vor Biopharma Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Vor Biopharma Inc. and its top competitor on Cyborg Score”
“What did Vor Biopharma Inc. do this quarter?”
“Is Vor Biopharma Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Vor Biopharma Inc. do?+
Vor Biopharma is a clinical-stage cell and genome engineering company developing the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. The company aims ...
What is Vor Biopharma Inc.'s Cyborg Score?+
Vor Biopharma Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Vor Biopharma Inc.'s main competitors?+
Named competitors include CAR-T Immunotherapy, Engineered Cell Therapy, Cancer Immunotherapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Vor Biopharma Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Vor Biopharma Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Vor Biopharma Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score